NM-2-AI
| NM-2-AI | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chemical Nomenclature | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common names | DMT, Dimethyltryptamine, Dmitri | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Substitutive name | N,N-Dimethyltryptamine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Systematic name | 2-(1H-Indol-3-yl)-N,N-dimethylethanamine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Class Membership | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Psychoactive class | Psychedelic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chemical class | Tryptamine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Routes of Administration | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Interactions | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Template:Proofread N-methyl-2-AI (N-methyl-2,3-dihydro-1H-inden-2-amine) is a psychoactive drug and research chemical with stimulant properties. Very little is known about this substance but it has recently become freely available through online research chemical vendors where it is being sold as a designer drug.
Chemistry
 |
This chemistry section is incomplete. You can help by adding to it. |
Pharmacology
Due to the lack of research regarding the substance, all discussion regarding the pharmacology of it is purely based upon its structure and subjective effect similarities to other stimulants such as amphetamine, methamphetamine and 2-FMA. N-methyl-2-AI most likely acts as both a dopamine and norepinephrine reuptake inhibitor. This means it effectively boosts the levels of the norepinephrine and dopamine neurotransmitters in the brain, by binding to, and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft. This allows dopamine and norepinephrine to accumulate within the brain, resulting in stimulating and euphoric effects.
Subjective effects
 |
This subjective effects section is a stub. As such, it is still in progress and may contain incomplete or wrong information. You can help by expanding or correcting it. |
Toxicity and harm potential
The toxicity and long term health effects of recreational N-methyl-2-AI use does not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because N-methyl-2-AI is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried N-methyl-2-AI suggests that there are no negative health effects attributed to simply trying this drug at low to moderate doses or using it very sparingly (but nothing can be completely guaranteed).
Tolerance and addiction potential
Tolerance develops rapidly with repeated usage, so periods of extended use require increasing doses of the drug in order to achieve the same effect. Addiction is a serious risk with heavy recreational use of any substituted amphetamine and compulsive redosing is extremely common.
Psychosis
Abuse of compounds within the amphetamine chemical class at high dosages for prolonged periods of time can result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, delusions).[2] A Cochrane Collaboration review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely.[3][4] The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis.[5] Psychosis very rarely arises from therapeutic use.[6][7]
Legal issues
2-AI is currently a grey area compound within all parts of the world. This means that it is not known to be specifically illegal within any country but that people may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.
See also
References
- ↑ APA formatted citation.
- ↑ Treatment for amphetamine psychosis | http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003026.pub3/abstract?systemMessage=Wiley+Online+Library+will+be+disrupted+Saturday%2C+15+March+from+10%3A00-12%3A00+GMT+%2806%3A00-08%3A00+EDT%29+for+essential+maintenance
- ↑ Treatment for amphetamine psychosis | http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003026.pub3/abstract?systemMessage=Wiley+Online+Library+will+be+disrupted+Saturday%2C+15+March+from+10%3A00-12%3A00+GMT+%2806%3A00-08%3A00+EDT%29+for+essential+maintenance
- ↑ Hofmann FG (1983). A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects (2nd ed.). New York: Oxford University Press. p. 329. ISBN 9780195030570.
- ↑ Treatment for amphetamine psychosis | http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003026.pub3/abstract?systemMessage=Wiley+Online+Library+will+be+disrupted+Saturday%2C+15+March+from+10%3A00-12%3A00+GMT+%2806%3A00-08%3A00+EDT%29+for+essential+maintenance
- ↑ Stimulant Misuse: Strategies to Manage a Growing Problem | http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf
- ↑ http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf
 |
This article does not cite enough references. You can help by adding some. |